Oligometastatic directed radiotherapy for patients with castration resistant prostate cancer.

Oligometastatic directed radiotherapy for patients with castration resistant prostate cancer. - OLYMPIAN

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON57227

Enrollment

Registered

2024-08-01

Start date

2025-01-03

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic prostate cancer oligoprogressive castraction resistant prostate cancer

Interventions

All patients eligible for the trial will be discussed at the multidisciplinary urology tumor board. The choice for MDRT will be based on the localization and size of the metastases, the nearby organ

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Adenocarcinoma of the prostate. • mCRPC setting, with testosterone level = 18 years old. • Patient should be presented at the multidisciplinary tumor board of the local hospital in which the therapy will be given. • Before patient registration, written informed consent must be given according to ICH/GCO and national/local regulations.

Exclusion criteria

Exclusion criteria: • Serum testosterone level > 50 ng/ml or > 1.7 nmol/l. • Presence of more than 3 progressive/new metastatic lesions and/or local recurrence (which counts for 1 lesion). • Active malignancy other than prostate cancer that can potentially interfere with the interpretation of the trial, except non-melanoma skin cancer or non-invasive urothelial cell carcinoma. • Local recurrence in the prostate after previous radiotherapy. • Previous treatments (RT, surgery) or comorbidities making new treatment with MDRT impossible. • Disorder precluding understanding of trial information or informed consent or signing informed consent. • Evidence of PSMA-negative disease.

Design outcomes

Primary

Measure	Time frame
• 6, 12-and 24-months NEST-FS. • 6- and 12- months rPFS.	—

Secondary

Measure	Time frame
• Quality of Life (QoL) evaluated using the EORTC QLQ-C30 for health related QoL and the EORTC PR-25 for prostate symptom specific QoL. • Acute and late toxicity reported using both physician-reported score (CTCAE v5) and patient-reported questionnaires (RTOG/EORTC). • Overall survival (OS).	—

Countries

Netherlands

Contacts

Public ContactS. Aluwini

Universitair Medisch Centrum Groningen

s.al-uwini@umcg.nl0625649975

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)